Artelo Biosciences (ARTL) News Today $1.16 -0.04 (-3.33%) Closing price 02/21/2025 03:56 PM EasternExtended Trading$1.15 -0.01 (-0.52%) As of 02/21/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Head-To-Head Contrast: Artelo Biosciences (NASDAQ:ARTL) versus Rafael (NYSE:RFL)February 20 at 2:07 AM | americanbankingnews.comArtelo Biosciences reports promising nonclinical CBD studyFebruary 14, 2025 | msn.comArtelo Biosciences announces new data on ART12.11February 14, 2025 | markets.businessinsider.comArtelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®February 14, 2025 | globenewswire.comArtelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, SwitzerlandFebruary 11, 2025 | globenewswire.comArtelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12January 13, 2025 | globenewswire.comOptimistic Buy Rating for Artelo Biosciences Based on Promising Developments in Cancer Anorexia TreatmentDecember 10, 2024 | markets.businessinsider.comArtelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related AnorexiaDecember 9, 2024 | globenewswire.comArtelo Biosciences to present key data on 3 development programsNovember 18, 2024 | markets.businessinsider.comArtelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development SummitNovember 18, 2024 | globenewswire.comArtelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumNovember 13, 2024 | globenewswire.comArtelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” ProgramNovember 5, 2024 | globenewswire.comArtelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16thOctober 9, 2024 | globenewswire.comArtelo Biosciences shares initiated with Buy by EF HuttonOctober 3, 2024 | uk.investing.comBuy Rating on Artelo Biosciences Amidst Promising Clinical Advancements and Portfolio DiversificationSeptember 11, 2024 | markets.businessinsider.comArtelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comArtelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comArtelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorJuly 15, 2024 | globenewswire.comArtelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumJuly 3, 2024 | globenewswire.comArtelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyJune 4, 2024 | globenewswire.comArtelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24May 29, 2024 | globenewswire.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | globenewswire.comArtelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thMay 10, 2024 | globenewswire.comArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyApril 23, 2024 | globenewswire.comArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeApril 22, 2024 | globenewswire.comRecap: Artelo Biosciences Q4 EarningsMarch 25, 2024 | benzinga.comArtelo Biosciences GAAP EPS of -$3.14 misses by $0.58March 25, 2024 | msn.comArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeMarch 12, 2024 | globenewswire.comArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thFebruary 15, 2024 | finanznachrichten.deArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12January 8, 2024 | finance.yahoo.comArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyDecember 5, 2023 | finance.yahoo.comPromising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating RecommendationNovember 16, 2023 | markets.businessinsider.comArtelo Biosciences GAAP EPS of -$0.83 misses by $0.18November 13, 2023 | msn.comArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comArtelo Biosciences Inc ARTLNovember 7, 2023 | morningstar.comArtelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023November 2, 2023 | finance.yahoo.comArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13thSeptember 5, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)August 11, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.June 28, 2023 | markets.businessinsider.comArtelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic PainJune 27, 2023 | msn.comArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society SymposiumJune 27, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)May 18, 2023 | markets.businessinsider.comArtelo Biosciences: Q1 Earnings InsightsMay 11, 2023 | msn.comArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | finance.yahoo.comArtelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossApril 25, 2023 | finance.yahoo.comArtelo Biosciences (ARTL) Gets a Buy from Maxim GroupApril 4, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.April 3, 2023 | markets.businessinsider.comArtelo Biosciences GAAP EPS of -$3.56April 2, 2023 | seekingalpha.com Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTL Media Mentions By Week ARTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTL News Sentiment▼0.000.60▲Average Medical News Sentiment ARTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTL Articles This Week▼10▲ARTL Articles Average Week Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biomerica News Eagle Pharmaceuticals News HCW Biologics News Cingulate News CervoMed News Phio Pharmaceuticals News Minerva Neurosciences News Trinity Biotech News Cellectar Biosciences News ImmunoPrecise Antibodies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
